APCyc: AI Framework for Designing Cyclic Peptides with Optimized Drug Properties
Researchers have introduced APCyc, a generative AI framework for designing cyclic peptides that explicitly models cyclization patterns and optimizes multiple drug-relevant properties simultaneously. Cyclic peptides are a promising therapeutic class but have been difficult to design computationally because most existing generative models were trained on linear peptide data. The work, accepted at KDD 2026, could accelerate drug discovery by enabling more targeted and controllable cyclic peptide generation.
APCyc is a target-aware de novo cyclic peptide generation framework developed to address a key gap in computational drug design: existing generative models are predominantly trained on linear peptide data and struggle to capture the structural and chemical constraints specific to cyclic peptides. The system uses an expanded residue vocabulary and explicitly encodes cyclization-site and linkage-type information, allowing it to learn cyclization-aware molecular representations. It then applies Bayesian posterior guidance to steer the generative sampling process toward candidates that satisfy multiple physicochemical property objectives at once. Experimental results reported by the authors indicate that APCyc learns target-dependent cyclization preferences, meaning it adapts its design strategy based on the binding pocket of a given protein target. Cyclic peptides are of significant interest in drug discovery because their ring structure generally confers greater metabolic stability and binding affinity compared to linear counterparts. The framework's source code has been made publicly available, and the paper has been accepted at the 32nd ACM SIGKDD Conference on Knowledge Discovery and Data Mining (KDD 2026).
What's missing
The abstract does not detail the specific benchmarks or datasets used for evaluation, the scale of experimental validation (e.g., whether wet-lab synthesis and testing were performed or results are purely computational), or how APCyc compares quantitatively to existing cyclic peptide design baselines. The degree to which computational property predictions translate to real-world therapeutic efficacy remains an open question.
What different sources said
- arXiv cs.AICenter
APCyc: Property-Informed Design of Cyclic Peptides via Automated Cyclization
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.